Home / Business and Economy / Oxford Biomedica Revenue Surges 9% Amid Client Growth
Oxford Biomedica Revenue Surges 9% Amid Client Growth
23 Sep
Summary
- Revenue grew 9% to £79.8 million in H1 2026, with a 10% constant currency increase.
- Seventeen new clients were secured in H1 2026, expanding the portfolio to 59 programs.
- Full-year revenue guidance of £180-200 million was reiterated, targeting £500 million by 2030.
Oxford Biomedica plc announced a revenue of £79.8 million for the first half of 2026, a 9% increase from the previous year's £73.2 million. This growth was bolstered by a 10% constant currency revenue increase and a significant expansion in client acquisition, with 17 new clients signed during the period, bringing the total client program portfolio to 59.
The company's adjusted operating EBITDA loss narrowed to £2.5 million from £3.9 million in the prior year. However, the gross margin decreased to 37% from 43%, attributed to product mix and one-off comparatives. An impairment charge of £7.6 million impacted results due to revised expectations for its France operations.
Looking ahead, Oxford Biomedica reaffirmed its full-year 2026 revenue guidance between £180-200 million and its medium-term objective of achieving approximately £500 million in revenue by 2030. The company's revenue backlog stood at £193 million as of June 30, 2026.
